GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinopharm Group Co Ltd (OTCPK:SHTDF) » Definitions » Total Equity

Sinopharm Group Co (Sinopharm Group Co) Total Equity : $0 Mil (As of Sep. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Sinopharm Group Co Total Equity?

Sinopharm Group Co's total equity for the quarter that ended in Sep. 2023 was $0 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.


Sinopharm Group Co Total Equity Historical Data

The historical data trend for Sinopharm Group Co's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinopharm Group Co Total Equity Chart

Sinopharm Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10,969.87 13,754.89 15,645.98 15,788.00 16,850.89

Sinopharm Group Co Quarterly Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 15,788.00 15,794.48 - 16,850.89

Sinopharm Group Co Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Sinopharm Group Co's Total Equity for the fiscal year that ended in Dec. 2022 is calculated as

Total Equity=Total Assets(Q: Dec. 2022 )-Total Liabilities(Q: Dec. 2022 )
=52322.265-36534.266
=15,788

Sinopharm Group Co's Total Equity for the quarter that ended in Sep. 2023 is calculated as

Total Equity=Total Assets(Q: Sep. 2023 )-Total Liabilities(Q: Sep. 2023 )
=N/A-N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinopharm Group Co Total Equity Related Terms

Thank you for viewing the detailed overview of Sinopharm Group Co's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinopharm Group Co (Sinopharm Group Co) Business Description

Traded in Other Exchanges
Address
No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023
Sinopharm Group was founded in 2003 and listed on the Hong Kong Stock Exchange in September 2009. Its main business is drug distribution in mainland China, which contributes about 75% of total revenue. It is the largest drug distributor, with approximately 20% market share. Other notable segments are medical device distribution, which contributes about 20% of revenue, and retail pharmacies, which contributes about 5%. These are fast-growing industries, where government policy is designed to encourage consolidation and promote large players with scale and efficiency advantages.

Sinopharm Group Co (Sinopharm Group Co) Headlines

From GuruFocus

Matthews China Fund Q3 2014 Commentary

By Holly LaFon Holly LaFon 10-18-2014

Matthews China Fund Comments on Sinopharm

By Holly LaFon Holly LaFon 05-19-2016

Matthews China Fund 1st Quarter Commentary

By Holly LaFon Holly LaFon 05-19-2016

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood 01-25-2021

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood 07-30-2020

Matthews China Fund Comments on Sinopharm Group

By Vera Yuan Vera Yuan 10-20-2014